{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:52:02Z","timestamp":1792540322443,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013281","name":"Joint Programming Initiative on Antimicrobial Resistance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cmi.2023.09.019","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T10:26:29Z","timestamp":1696415189000},"page":"718-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections"],"prefix":"10.1016","volume":"30","author":[{"given":"Simone","family":"Tunesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Zelazny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Mougari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien M.","family":"Buyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Cambau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.09.019_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2023.09.019_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib3","article-title":"Nontuberculous mycobacterial ocular infections\u2014comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense","volume":"10","author":"Chu","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2023.09.019_bib4","doi-asserted-by":"crossref","unstructured":"Cristancho-Rojas C, Varley CD, Lara SC, Kherabi Y, Henkle E, Winthrop KL. Epidemiology of Mycobacterium abscessus. Clin Microbiol Infect 2024;30:712\u2013717","DOI":"10.1016\/j.cmi.2023.08.035"},{"key":"10.1016\/j.cmi.2023.09.019_bib5","doi-asserted-by":"crossref","unstructured":"Lagune M, Kremer L, Herrmann J-L. Mycobacterium abscessus, a complex of three fast-growing subspecies sharing virulence traits with slow-growing mycobacteria. Clin Microbiol Infect 2024;30:726\u2013731.","DOI":"10.1016\/j.cmi.2023.08.036"},{"key":"10.1016\/j.cmi.2023.09.019_bib6","doi-asserted-by":"crossref","unstructured":"Palucci I, Delogu G. Alternative therapies against Mycobacterium abscessus infections. Clin Microbiol Infect 2024;30:732\u2013737.","DOI":"10.1016\/j.cmi.2023.10.001"},{"key":"10.1016\/j.cmi.2023.09.019_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1473-3099(04)01130-2","article-title":"Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy","volume":"4","author":"Karakousis","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/ajrccm\/147.5.1271","article-title":"Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients","volume":"147","author":"Griffith","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","article-title":"Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients","volume":"180","author":"Jeon","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2023.09.019_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091879","article-title":"Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study","volume":"9","author":"Mirsaeidi","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2023.09.019_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12864-016-2448-1","article-title":"Genome-wide mosaicism within Mycobacterium abscessus: evolutionary and epidemiological implications","volume":"17","author":"Sapriel","year":"2016","journal-title":"BMC Genomics"},{"key":"10.1016\/j.cmi.2023.09.019_bib13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","article-title":"Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus","volume":"183","author":"Koh","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2023.09.019_bib14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A\u00a0novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards clinical breakpoints for non-tuberculous mycobacteria \u2013 determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution","volume":"29","author":"Fr\u00f6berg","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.09.019_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cmi.2023.06.005","article-title":"Appeal from the European reference laboratory network for tuberculosis for improving the diagnosis of infections caused by non-tuberculous mycobacteria","volume":"30","author":"Tagliani","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.09.019_bib18","series-title":"Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. CLSI document M62Ed1","author":"Woods","year":"2018"},{"key":"10.1016\/j.cmi.2023.09.019_bib19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/JCM.38.2.656-661.2000","article-title":"Multisite reproducibility of etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum","volume":"38","author":"Woods","year":"2000","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.09.019_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/pathogens11090969","article-title":"High rates of antimicrobial resistance in rapidly growing mycobacterial infections in Taiwan","volume":"11","author":"Tu","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.cmi.2023.09.019_bib21","first-page":"547","article-title":"A\u00a0comparison between disk diffusion and microdilution for susceptibility testing of Mycobacterium fortuitum complex","volume":"14","author":"Esteban","year":"2002","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib22","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.3390\/microorganisms9122562","article-title":"Evolution of antibacterial drug screening methods: current prospects for mycobacteria","volume":"9","author":"Bento","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2023.09.019_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01919-18","article-title":"In\u00a0vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex","volume":"63","author":"Brown-Elliott","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib25","article-title":"In\u00a0vitro activity of oxazolidinone against nontuberculous mycobacteria, including macrolide-resistant clinical isolates","volume":"65","author":"Kim","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02346-21","article-title":"In\u00a0vitro bedaquiline and clofazimine susceptibility testing in Mycobacterium abscessus","volume":"66","author":"Schulthess","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2023.09.019_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00470-19","article-title":"In\u00a0vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02522-18","article-title":"In\u00a0vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-20","article-title":"In\u00a0vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/dkaa520","article-title":"In\u00a0vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens","volume":"76","author":"Chew","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib32","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3389\/fmicb.2018.02179","article-title":"The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance","volume":"9","author":"Luthra","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2023.09.019_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cmi.2023.09.019_bib34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12864-022-08941-7","article-title":"The resistomes of Mycobacteroides abscessus complex and their possible acquisition from horizontal gene transfer","volume":"23","author":"Chong","year":"2022","journal-title":"BMC Genomics"},{"key":"10.1016\/j.cmi.2023.09.019_bib35","doi-asserted-by":"crossref","first-page":"46S","DOI":"10.1046\/j.1365-2672.92.5s1.7.x","article-title":"Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria","volume":"92","author":"Lambert","year":"2002","journal-title":"J\u00a0Appl Microbiol"},{"key":"10.1016\/j.cmi.2023.09.019_bib36","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1042\/BST0331000","article-title":"ABC proteins and antibiotic drug resistance: is it all about transport?","volume":"33","author":"Kerr","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.cmi.2023.09.019_bib37","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/jac\/dkw130","article-title":"Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar","volume":"71","author":"Mougari","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1128\/AAC.00861-10","article-title":"Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing","volume":"55","author":"Bastian","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A \u03b2-lactamase","volume":"69","author":"Soroka","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib40","unstructured":"Torres MP, Hanemaaijer N, van Ingen J. Dual-beta-lactam therapies for M. abscessus \u2013 a review and road map for clinical implementation. submitted for publication in CMI"},{"key":"10.1016\/j.cmi.2023.09.019_bib41","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/jac\/dkx125","article-title":"Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes","volume":"72","author":"Rominski","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00119-18","article-title":"High levels of intrinsic tetracycline resistance in Mycobacterium abscessus are conferred by a tetracycline-modifying monooxygenase","volume":"62","author":"Rudra","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2023.09.019_bib44","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jac\/dkw466","article-title":"Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591","volume":"72","author":"Rominski","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib45","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib46","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1128\/AAC.42.8.2084","article-title":"Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria","volume":"42","author":"Guillemin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib47","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1128\/AAC.01380-07","article-title":"Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones","volume":"52","author":"Matrat","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01353-17","article-title":"Antagonism between front-line antibiotics clarithromycin and amikacin in the treatment of Mycobacterium abscessus infections is mediated by the whiB7 gene","volume":"61","author":"Pryjma","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib49","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1086\/515328","article-title":"A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae","volume":"177","author":"Prammananan","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib50","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/jac\/dkr209","article-title":"Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus","volume":"66","author":"Nessar","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/AAC.38.2.381","article-title":"Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare","volume":"38","author":"Meier","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00544-18","article-title":"Novel mutations associated with clofazimine resistance in Mycobacterium abscessus","volume":"62","author":"Chen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01000-19","article-title":"The TetR family transcription factor MAB_2299c regulates the expression of two distinct mmps-mmpl efflux pumps involved in cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus","volume":"63","author":"Guti\u00e9rrez","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01316-18","article-title":"Mutations in the MAB_2299c TetR regulator confer cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus","volume":"63","author":"Richard","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib55","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/jac\/dkx021","article-title":"Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria","volume":"72","author":"Mougari","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.05041-22","article-title":"Subspecies distribution and antimicrobial susceptibility testing of Mycobacterium abscessus clinical isolates in Madrid, Spain: a retrospective multicenter study","volume":"11","author":"Ruedas-L\u00f3pez","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2023.09.019_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239146","article-title":"Evaluation of the GenoType NTM-DR assay performance for the identification and molecular detection of antibiotic resistance in Mycobacterium abscessus complex","volume":"15","author":"Bouzinbi","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2023.09.019_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00516-19","article-title":"GenoType NTM-DR performance evaluation for identification of Mycobacterium avium complex and Mycobacterium abscessus and determination of clarithromycin and amikacin Resistance","volume":"57","author":"Huh","year":"2019","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.09.019_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00943-16","article-title":"Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies","volume":"61","author":"Mougari","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib60","article-title":"Whole-genome sequencing for predicting clarithromycin resistance in Mycobacterium abscessus","volume":"63","author":"Lipworth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770518","article-title":"Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward","volume":"12","author":"Landersdorfer","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2023.09.019_bib62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.diagmicrobio.2018.06.015","article-title":"The stability of antimycobacterial drugs in media used for drug susceptibility testing","volume":"92","author":"Schoutrop","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis"},{"key":"10.1016\/j.cmi.2023.09.019_bib64","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1128\/AAC.02924-15","article-title":"Susceptibility testing of antibiotics that degrade faster than the doubling time of slow-growing mycobacteria: ertapenem sterilizing effect versus Mycobacterium tuberculosis","volume":"60","author":"Srivastava","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106847","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus Disease","author":"Singh","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2023.09.019_bib66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cmi.2018.03.047","article-title":"Pharmacokinetics\/pharmacodynamics characterization of combined antimicrobial agents: a real challenge and an urgent need","volume":"24","author":"Couet","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.09.019_bib67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/dkx380","article-title":"A\u00a0model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations","volume":"73","author":"Clewe","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jgar.2022.10.015","article-title":"Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: the potential role of efflux pumps","volume":"31","author":"Mudde","year":"2022","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2023.09.019_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in\u00a0vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib70","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.3390\/ijms22126346","article-title":"Activity of oritavancin and its synergy with other antibiotics against Mycobacterium abscessus infection in vitro and in vivo","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2023.09.019_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02651-18","article-title":"Preclinical pharmacokinetic and pharmacodynamic data to support cefoxitin nebulization for the treatment of Mycobacterium abscessus","volume":"63","author":"Mehta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib72","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The role of amikacin in the treatment of nontuberculous mycobacterial disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cmi.2023.09.019_bib73","article-title":"Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 6","volume":"62","author":"Marchand","year":"2018","journal-title":"Aminoglycosides. Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib74","article-title":"PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus","volume":"24","author":"Anversa Dimer","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cmi.2023.09.019_bib75","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/pharmaceutics13071070","article-title":"Rifampicin\u2013liposomes for Mycobacterium abscessus infection treatment: intracellular uptake and antibacterial activity evaluation","volume":"13","author":"Rinaldi","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2023.09.019_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49556-5","article-title":"Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection","volume":"9","author":"Kloprogge","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2023.09.019_bib77","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/antibiotics10121515","article-title":"Improving the drug development pipeline for mycobacteria: modelling antibiotic exposure in the hollow fibre infection model","volume":"10","author":"Maitra","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.cmi.2023.09.019_bib78","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin pharmacokinetics\/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model","volume":"60","author":"Ferro","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011559","article-title":"Druggable redox pathways against M. abscessus in cystic fibrosis patient-derived airway organoids","author":"Leon-Icaza","year":"2023","journal-title":"Plos Pathogen"},{"key":"10.1016\/j.cmi.2023.09.019_bib80","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jit614","article-title":"In\u00a0vivo evaluation of antibiotic activity against Mycobacterium abscessus","volume":"209","author":"Lerat","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102301","article-title":"Preclinical murine models to study lung infection with Mycobacterium abscessus complex","volume":"138","author":"Nicola","year":"2023","journal-title":"Tuberculosis"},{"key":"10.1016\/j.cmi.2023.09.019_bib82","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.3390\/ijms21186590","article-title":"A\u00a0new model of chronic Mycobacterium abscessus lung infection in immunocompetent mice","volume":"21","author":"Riva","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2023.09.019_bib83","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02212-21","article-title":"A\u00a0rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: macrolide case study","volume":"66","author":"Kaya","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib84","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib85","doi-asserted-by":"crossref","DOI":"10.4172\/2161-1068.1000216","article-title":"Animal models of non-tuberculous mycobacterial infections","volume":"6","author":"Chan","year":"2016","journal-title":"Mycobact Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccm.2021.11.007","article-title":"Nontuberculous mycobacteria: diagnosis and therapy","volume":"43","author":"Varley","year":"2022","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.cmi.2023.09.019_bib87","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.2147\/IDR.S373783","article-title":"Early-phase adverse effects and management of liposomal amikacin inhalation for refractory Mycobacterium avium complex lung disease in real-world settings","volume":"15","author":"Morita","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2023.09.019_bib88","doi-asserted-by":"crossref","first-page":"ofac465","DOI":"10.1093\/ofid\/ofac465","article-title":"Amikacin liposomal inhalation suspension in the treatment of Mycobacterium abscessus lung infection: a French observational experience","volume":"9","author":"Chiron","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib89","series-title":"B19. Advances in the treatment of NTM","article-title":"Open-Label trial of amikacin liposome inhalation suspension in M. abscessus lung disease","author":"Siegel","year":"2019"},{"key":"10.1016\/j.cmi.2023.09.019_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib91","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab093","article-title":"Tedizolid vs linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients","volume":"8","author":"Poon","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2023.09.019_bib92","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01919-18","article-title":"In\u00a0vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex","volume":"63","author":"Brown-Elliott","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.09.019_bib93","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"Van Ingen","year":"2018","journal-title":"Eur Respir J"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23004822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23004822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T01:48:04Z","timestamp":1748742484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23004822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1198743X23004822"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.09.019","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}